Infectious Disease
| Current Project | Investigator | Site |
| A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Septic Intensive Care Unit Patients (LOVIT) | Dr. J Kutsogiannis | RAH-ICU |
| Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) | Dr. J Kutsogiannis Dr. W Sligl |
GSICU RAH-ICU |
| Neurological Complications of COVID 19 | Dr. J Kutsogiannis | RAH-ICU |
| Canadian Severe Acute Infection Outbreak and Pandemic Preparedness Study: Short Period Incidence Study of Severe Acute Respiratory Infection (Sprint-Sari) | Dr. J Kutsogiannis Dr. O Rewa |
|
| A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO) | Dr. J Kutsogiannis Dr. G Singh |
RAH-ICU |
| Lessening Organ Dysfunction with VITamin C; A Multicentre Concealed-Allocation Parallel-Group Blinded Randomized Controlled Trial to Ascertain the Effect of High-Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Hospitalized Patients with COVID-19 (Lovit-Covid) | Dr. J Kutsogiannis | RAH-ICU |
| A Multi-centre, Adaptive, Randomized, open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO) In Conjunction with the Public Health Emergency Solidarity Trial | Dr. C O'Neil Dr. E MacIntyre |
MIS-ICU |
| Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Randomized Controlled Trial (BALANCE) | Dr. W Sligl | GSICU |
| The ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (ECMO-CARD) | Dr. W Sligl | GSICU |
| Immune Response & Immune Function | Dr. W Sligl | GSICU |
| A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO) | Dr. N Lee | GSICU |